Abstract 7370: End-to-end in vitro and in vivo evaluation of radiopharmaceuticals in patient-derived models

Key Points

• The aim is to evaluate the effectiveness and safety of radiopharmaceuticals in patient-derived cancer models.
• Developed PSMA-617 radiolabeled with 68Ga and 177Lu.
• Conducted in vitro assays using 2D and 3D patient-derived models (PDXO, CDX).
• Applied immunofluorescence to assess DNA damage in prostate cancer cells.
• Utilized PET imaging for monitoring tumor response in vivo.
• Monitored tumor growth and body weight in PDX models after radiopharmaceutical treatment.
• Achieved >95% radiochemical purity of labeled PSMA-617.
• Demonstrated differential tumor responses to treatment based on PSMA expression levels.
• Supported findings with diagnostic PET imaging across models.